Both EGFR and MET pathways have been implicated in driving tumor growth in lung cancer [11,70–72] and in particular, MET pathway activation via upregulation of MET expression has frequently been described a mechanism of EGFR kinase inhibitor resistance [73,74]. The gene discussed is MET; the disease is lung carcinoma.